A venture formation and investment firm focuses on identifying and developing overlooked or underutilized therapeutic assets to address critical unmet medical needs. The firm typically acquires or licenses these assets and builds new companies around them, working closely with experienced executives and strategic partners to drive development and long-term value creation. The firm prefers opportunities where assets are not already tied to established commercial or private entities, allowing the firm to play a primary role in venture creation. The firm engages with opportunities globally and, in addition to its venture studio model, also makes direct early-stage investments outside of company formation. 

The firm is open to a broad range of therapeutic assets and compounds, with a particular emphasis on small molecules. The firm is disease-agnostic but has a preference for oncology. The firm has also begun to explore opportunities in digital health technologies. The firm does not invest in medical devices. 

The firm does not impose strict requirements on companies or management teams. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

An investment platform with offices in Asia is backed by a large state-affiliated industrial group. The firm invests across the full company lifecycle, from early and incubation stages through growth and buyout opportunities, deploying capital through multiple funds. For early-stage investments, the firm typically deploys multi-million dollar checks with flexibility depending on the opportunity. The firm evaluates opportunities globally and has invested across key markets including North America, Europe, Israel, and Asia.  
 
Within life sciences and healthcare, the firm focuses on innovative therapeutics, medical devices, and healthcare services. The firm is open to companies across all stages of development, from preclinical through clinical and commercial stages.  
 
From a company and management team perspective, the firm seeks teams with strong industry and clinical expertise, solid scientific foundations, and globally competitive positioning supported by robust intellectual property. The firm leverages close relationships with industrial partners and an established regional network to support portfolio companies in advancing development and expanding into the China market. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

The firm is a privately held life sciences investment vehicle focused on funding clinical development in exchange for equity and warrants. The firm primarily invests in publicly traded companies and structures investments to directly support clinical trials and related services. Typical allocations range from approximately $2M to $6M, with the ability to deploy additional capital through tranche financings. The firm focuses on companies conducting clinical trials in the United States. 
 

The firm is active across therapeutics, diagnostics, and medical devices and is generally agnostic to technology type and disease indication. The firm is particularly interested in companies that are entering or currently in proof-of-concept clinical trials, typically at Phase Ib or Phase IIa stages. 
 

From a company and management team perspective, the firm seeks publicly traded companies with experienced leadership teams and actively engaged boards of directors. The firm is open to both leading and co-investing. While the firm primarily invests in public companies, it remains open to engaging early with emerging clinical-stage opportunities ahead of formal investment readiness. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

A global life sciences advisory and venture capital firm provides strategic advisory services alongside direct venture investments in biotechnology, pharmaceutical, medical device, and digital health companies. The firm maintains an international investment portfolio spanning multiple healthcare sectors and collaborates with companies and institutions across North America, Europe, and other global markets. In addition to capital, the firm supports portfolio companies through strategic guidance in product development, regulatory planning, and commercialization strategy.  

The firm invests across therapeutics, medical technologies, diagnostics, digital health, and platform-based innovations that address major unmet clinical needs. Areas of activity include oncology, infectious diseases, neurology, immunology, women’s health, and device-enabled interventions, as well as computational and data-driven healthcare approaches. The firm prioritizes opportunities with strong scientific rationale, translational potential, and clear regulatory and commercial pathways.  

From a company and management team perspective, the firm partners with teams demonstrating scientific credibility, disciplined development planning, and operational capability to advance programs efficiently through key milestones. The firm values strong intellectual property positions, robust preclinical or clinical data packages, and clearly defined global development and market entry strategies. Leveraging its combined investment and advisory capabilities, the firm supports companies through integrated guidance across R&D, regulatory strategy, clinical development, business development, and commercialization. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

The firm is a joint venture investment vehicle established by a family office and a strategic investment partner. The firm focuses on later-stage medical device opportunities, particularly Series A and Series B companies approaching regulatory approval. The firm primarily evaluates opportunities in the United States and Western Europe, while remaining open to select companies based in Asia. Typical check sizes range from approximately $500K to $1.5M, and the firm prefers to lead transactions. The firm may also co-invest alongside affiliated investment vehicles to support later-stage, revenue-generating companies that demonstrate a clear path to exit within a relatively short time horizon. Through long-standing industry relationships, the firm helps introduce portfolio companies into a specialized medical technology ecosystem to accelerate growth and commercialization.  

The firm evaluates opportunities across medical device categories but maintains a strong focus on implantable technologies. Core areas of interest include neuromuscular and musculoskeletal indications, particularly orthopedic and spine implants. The firm also reviews opportunities in cardiology, vascular and peripheral devices, surgical technologies, and select oncology-related technologies. Companies should typically be approaching regulatory approval and demonstrate validated technology and clinical utility.  

From a company and management team perspective, the firm requires board representation and at minimum takes an observer seat in portfolio companies. The firm seeks companies with proven technology, clear regulatory pathways, and strong commercial potential within established clinical markets. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

An investment manager founded in 2021 and headquartered in Asia primarily operates as a fund-of-funds, allocating capital to healthcare and life sciences-focused investment vehicles including venture capital, private equity, and public market funds. In addition to fund commitments, the firm also participates directly in company financings through special purpose vehicles.  

For direct investments, the firm takes a flexible approach but typically participates in later financing rounds after gaining a deeper understanding of the company and its development trajectory. The firm has no specific preference between leading or co-investing and evaluates opportunities globally.  

The firm is broadly interested in companies operating in biotechnology, medical technology, and digital health.  

The firm does not impose specific requirements regarding company structure or management team composition. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.